Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
Authors Esteban Jódar-Gimeno
Published Date May 2007 Volume 2007:2(1) Pages 163—174
Published 16 May 2007
Endocrinology and Metabolism Service, University Hospital “12 de Octubre”, Madrid, Spain. Associate Professor of Medicine Universidad Complutense, Madrid, Spain
Objective: To review the pharmacological properties and the available clinical data of full length parathyroid hormone (PTH) in post-menopausal osteoporosis.
Sources: A MEDLINE search was completed, together with a review of information obtained from the manufacturer and from the medicine regulatory agencies.
Study and data selection: Studies were selected according to relevance and availability. Relevant information (design, objectives, patients’ characteristics, outcomes, adverse events, dosing, etc) was analyzed.
Results: Different studies have shown that, when administered intermittently as a subcutaneous injection in the abdomen, PTH increases bone mineral density (BMD) and prevents vertebral fractures. On completion of PTH therapy (up to 24 months), there is evidence that sequential treatment with alendronate is associated with a therapeutic benefit in terms of increase in BMD. Further trials are necessary to determine long-term safety and the role of PTH in combination with other treatments for osteoporosis and the effect of repeated cycles of PTH followed by an anti-catabolic agent. There are currently no completed comparative trials with other osteoporosis treatments.
Conclusions: Full length PTH, given intermittently as an abdominal subcutaneous injection, appears to be a safe and efficacious treatment option for high risk osteoporosis. More data are needed to determine its specific role in osteoporosis treatment.
Keywords: postmenopausal osteoporosis, anabolic therapy, PTH (1–84)
Readers of this article also read:
Prevention and optimal management of sarcopenia: a review of combined exercise and nutrition interventions to improve muscle outcomes in older people
Denison HJ, Cooper C, Sayer AA, Robinson SM
Published Date: 11 May 2015
Nanda SS, An SS, Yi DK
Published Date: 12 January 2015
Impact of chronic obstructive pulmonary diseases on left ventricular diastolic function in hospitalized elderly patients
Huang YS, Feng YC, Zhang J, Bai L, Huang W, Li M, Sun Y
Published Date: 19 December 2014
Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM
Published Date: 16 April 2014
“Denervation” of autonomous nervous system in idiopathic pulmonary arterial hypertension by low-dose radiation: a case report with an unexpected outcome
Hohenforst-Schmidt W, Zarogoulidis P, Oezkan F, Mahnkopf C, Grabenbauer G, Kreczy A, Bartunek R, Darwiche K, Freitag L, Li Q, Huang H, Vogl T, LePilvert P, Tsiouda T, Tsakiridis K, Zarogoulidis K, Brachmann J
Published Date: 27 March 2014
Lewin GF, Alfonso HS, Alan JJ
Published Date: 2 October 2013
Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm [Corrigendum]
Tian XH, Wang ZG, Meng H, Wang YH, Feng W, Wei F, Huang ZC, Lin XN, Ren L
Published Date: 13 June 2013
Radiofrequency-targeted vertebral augmentation versus traditional balloon kyphoplasty: radiographic and morphologic outcomes of an ex vivo biomechanical pilot study [Erratum]
Published Date: 5 June 2013
Frequency and clinical relevance of human bocavirus infection in acute exacerbations of chronic obstructive pulmonary disease
Felix C Ringshausen, Ai-Yui M Tan, Tobias Allander, Irmgard Borg, Umut Arinir, et al
Published Date: 4 February 2009
Meheroz H Rabadi, Bruce S Kristal
Published Date: 17 May 2007